Publication|Articles|February 11, 2025
Supplements and Featured Publications
- Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Listen
0:00 / 0:00
Advertisement
This Clinical Brief is supported by Boehringer Ingelheim.
This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil® 2, the first trial to study subcutaneous Spevigo® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
OpenAI for Healthcare Aims to Streamline Clinical Workflows, Reduce Administrative Burden
2
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
3
Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data
4
Postpandemic Nursing Home Capacity Declines Tied to Longer Hospital Stays, Increased Patient Travel
5
























































